Amarin Gets a Buy Rating from Jefferies

By Ryan Adsit

In a report released today, Eun Yang from Jefferies reiterated a Buy rating on Amarin (NASDAQ: AMRN), with a price target of $5. The company’s shares closed last Friday at $2.96.

According to TipRanks.com, Yang is a 3-star analyst with an average return of 0.8% and a 45.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Amarin is Strong Buy and the average price target is $6.67, representing a 125.3% upside.

In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $10 price target.

The company has a one year high of $3.65 and a one year low of $1.90. Currently, Amarin has an average volume of 1.23M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics for cardiovascular health. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.